nach oben

Current Psychiatry Reports

Erschienen in:

01.02.2016 | Sexual Disorders (G Dwyer, Section Editor)

The Biological Treatment of Paraphilic Disorders: an Updated Review

verfasst von: Brian J. Holoyda, Denise C. Kellaher

Erschienen in: Current Psychiatry Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Paraphilic disorders are characterized by atypical sexual interests, fantasies, and behaviors that are subjectively distressing to patients or pose a risk of harm to others. By their very nature, some paraphilic disorders may predispose an individual to commit sexual offenses. The biological treatment of paraphilic disorders, then, is of paramount importance for psychiatry and society at large. Three categories of pharmacologic agents commonly used to treat paraphilic disorders are selective serotonin reuptake inhibitors, synthetic steroidal analogs, and gonadotropin-releasing hormone analogs. Each medication uses a different mechanism of action and has different effects on the physiological and psychological features of paraphilic disorders. In general, these medications have limited high-quality research to support their use. Despite this, some authors have proposed treatment algorithms for individuals with paraphilic disorders of varying severity. These guidelines offer clinicians potentially useful, rational approaches to assessing treatment need in individuals with paraphilic disorders. Recent neuroimaging research suggests that functional magnetic resonance imaging may offer further promise in effectively assessing paraphilic disorders to help direct treatment options.

Krafft-Ebing RV. Psychopathia sexualis. 12th ed. New York: Pioneer Publications; 1950.

Laws DR, O’Donohue WT. Sexual deviance: theory, assessment, and treatment. 2nd ed. New York: Guilford Press; 2008.

Lösel F, Schmucker M. The effectiveness of treatment for sexual offenders: a comprehensive meta-analysis. J Exp Criminol. 2005;1(1):117–46.CrossRef

4.••

Dennis JA. Psychological interventions for adults who have sexually offended or are at risk of offending. Cochrane Database Syst Rev. 2012;12:CD007507. This important Cochrane review evaluated evidence from studies on psychological interventions for adults who sexually offend. They found no difference between treated and untreated groups in terms of the risk of reoffending, as measured by a new sexual crime conviction. They concluded that more research is needed. PubMed

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington: American Psychiatric Association; 2000.

7.••

American Psychiatric Association (2013). Paraphilic Disorders Fact Sheet. Available at: http://www.dsm5.org/Documents/Paraphilic%20Disorders%20Fact%20Sheet.pdf. This resource document from the American Psychiatric Association summarizes the changes made in the paraphilic diagnoses between DSM-IV-TR and DSM-5 . It also explains the Sexual and Gender Identity Disorders Work Group’s rationale for these changes.

First MB. DSM-5 and paraphilic disorders. J Am Acad Psychiatry Law. 2014;42(2):191–201.PubMed

9.••

Thibaut F. Pharmacological treatment of paraphilias. Isr J Psychiatry Relat Sci. 2012;49(4):297–305. This article provides a brief, cogent summary of the more extensive World Federation of Societies of Biological Psychiatry guidelines for the treatment of paraphilias. PubMed

10.

Thibaut F et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World J Biol Psychiatry. 2010;11(4):604–55.CrossRefPubMed

11.

Assumpcao AA et al. Pharmacologic treatment of paraphilias. Psychiatr Clin North Am. 2014;37(2):173–81.CrossRefPubMed

12.•

Garcia FD et al. Pharmacologic treatment of sex offenders with paraphilic disorder. Curr Psychiatry Rep. 2013;15(5):356. The authors discuss medications used to treat paraphilic disorders with a focus on individuals who have sexually offended. CrossRefPubMed

13.•

Bijlsma EY et al. Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release? Pharmacol Biochem Behav. 2014;121:88–101. The authors review the pharmacologic basis of the sexual side effects of selective serotonin reuptake inhibitors (SSRIs). They note that increasing dopamine neurotransmission overcomes the sexual side effects of SSRIs. They therefore hypothesize that the sexual side effects of SSRIs result from the inhibition of dopamine neurotransmission in sex brain circuits. CrossRefPubMed

14.

Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry. 2000;57(11):1012.CrossRefPubMed

15.

Rosler A, Witztum E. Pharmacotherapy of paraphilias in the next millennium. Behav Sci Law. 2000;18(1):43–56.CrossRefPubMed

16.

Garcia FD, Thibaut F. Current concepts in the pharmacotherapy of paraphilias. Drugs. 2011;71(6):771–90.CrossRefPubMed

17.

Adi Y et al. Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. Health Technol Assess. 2002;6(28):1–66.PubMed

18.

Bradford JM. The treatment of sexual deviations using a pharmacological approach. J Sex Res. 2000;37(3):248–57.CrossRef

19.

Bradford J, Federoff JP. Pharmacological treatment of the juvenile sex offender. In: Barbaree HE, Marshall WL, editors. The juvenile sex offender. New York: Guilford Press; 2006. p. 358–82.

20.

Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996;153(8):974–84.CrossRefPubMed

21.

Bradford JM, Bourget D. Sexually aggressive men. Psychiatr J Univ Ott. 1987;12(3):169–75.PubMed

22.

Bradford JM, McLean D. Sexual offenders, violence and testosterone: a clinical study. Can J Psychiatry. 1984;29(4):335–43.PubMed

23.

Seim HC, Dwyer M. Evaluation of serum testosterone and luteinizing hormone levels in sex offenders. Fam Pract Res J. 1988;7(3):175–80.PubMed

24.

Craissati J. Managing high risk sex offenders in the community: a psychological approach. New York: Routledge; 2004.

25.

Saleh FM, Berlin FS. Sex hormones, neurotransmitters, and psychopharmacological treatments in men with paraphilic disorders. J Child Sex Abus. 2003;12(3–4):233–53.CrossRefPubMed

26.

Brady BM et al. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male. Clin Endocrinol (Oxf). 2003;58(4):506–12.CrossRef

27.

Berlin FS. The paraphilias and Depo-Provera: some medical, ethical and legal considerations. Bull Am Acad Psychiatry Law. 1989;17(3):233–9.PubMed

28.

Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther. 2009;31(1):1–31.CrossRefPubMed

29.••

Khan O et al. Pharmacological interventions for those who have sexually offended or are at risk of offending. Cochrane Database Syst Rev. 2015;2:CD007989. This Cochrane review summarizes current available research on the utility of pharmacologic treatments in sexual offenders. It highlights the paucity of high-quality research in this area. PubMed

30.

Jeffcoate WJ et al. The effect of cyproterone acetate on serum testosterone, LH, FSH, and prolactin in male sexual offenders. Clin Endocrinol (Oxf). 1980;13(2):189–95.CrossRef

31.

Gijs L, Gooren L. Hormonal and psychopharmacological interventions in the treatment of paraphilias: an update. J Sex Res. 1996;33(4):237–90.CrossRef

32.

Meyer JW, Cole CM. Physical and chemical castration of sex offenders: a review. J Offender Rehabil. 1997;25(3–4):1–18.

33.

Conn PM, Crowley Jr WF. Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991;324(2):93–103.CrossRefPubMed

34.

Belchetz PE et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631–3.CrossRefPubMed

35.

Thibaut F, Cordier B, Kuhn JM. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand. 1993;87(6):445–50.CrossRefPubMed

36.

Briken P. Pharmacotherapy of paraphilias with luteinizing hormone-releasing hormone agonists. Arch Gen Psychiatry. 2002;59(5):469–70.CrossRefPubMed

37.

Czerny JP, Briken P, Berner W. Antihormonal treatment of paraphilic patients in German forensic psychiatric clinics. Eur Psychiatry. 2002;17(2):104–6.CrossRefPubMed

38.

Hill A et al. Differential pharmacological treatment of paraphilias and sex offenders. Int J Offender Ther Comp Criminol. 2003;47(4):407–21.CrossRefPubMed

39.

Maletzky BM, Field G. The biological treatment of dangerous sexual offenders: a review and preliminary report of the Oregon pilot depo-Provera program. Aggress and Violent Behav. 2003;8:391–412.CrossRef

40.

Maletzky BM, Tolan A, McFarland B. The Oregon depo-Provera program: a five-year follow-up. Sex Abuse. 2006;18(3):303–16.PubMed

41.

Ferretti A et al. Dynamics of male sexual arousal: distinct components of brain activation revealed by fMRI. Neuroimage. 2005;26(4):1086–96.CrossRefPubMed

42.

Karama S et al. Areas of brain activation in males and females during viewing of erotic film excerpts. Hum Brain Mapp. 2002;16(1):1–13.CrossRefPubMed

43.

Mouras H et al. Brain processing of visual sexual stimuli in healthy men: a functional magnetic resonance imaging study. Neuroimage. 2003;20(2):855–69.CrossRefPubMed

44.••

Cheng JC et al. Neuroimaging and sexual behavior: identification of regional and functional differences. Curr Psychiatry Rep. 2015;17:55. The authors summarize neuroimaging findings in sexual behavior and their relevance in sexual disorders including pedophilic disorder and compulsive sexual behavior.

45.••

Wiebking C, Northoff G. Neuroimaging in pedophilia. Curr Psychiatry Rep. 2013;15(4):351. The authors provide a comprehensive summary of the use of neuroimaging in the assessment of pedophilic disorder. In addition, they discuss the potential use of neurofeedback to augment treatment of pedophilic disorder. CrossRefPubMed

46.

Renaud P et al. Real-time functional magnetic imaging—brain-computer interface and virtual reality promising tools for the treatment of pedophilia. Prog Brain Res. 2011;192:263–72.CrossRefPubMed

47.••

Kärgel C et al. Diminished functional connectivity on the road to child sexual abuse in pedophilia. J Sex Med. 2015;12(3):783–95. The authors identified differences in the functional connectivity at rest (a measure of resting neural activity) between pedophiles who had committed child sexual abuse and those who had not. This suggests that fMRI may assist in identifying pedophilic individuals who are at a higher risk of engaging in sexual crimes. CrossRefPubMed

Titel: The Biological Treatment of Paraphilic Disorders: an Updated Review
verfasst von: Brian J. Holoyda
Denise C. Kellaher
Publikationsdatum: 01.02.2016
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 2/2016
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-015-0649-y

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Biological Treatment of Paraphilic Disorders: an Updated Review

Abstract

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Recidivism Risk Assessment for Adult Sexual Offenders

Dreams and Nightmares in Personality Disorders

Special Needs: Scholastic Disability Accommodations from K-12 and Transitions to Higher Education

Identification and Management of Chronic Pain in Primary Care: a Review

Bipolar Disorder in Pregnancy and Postpartum: Principles of Management

Prevention of Post-Traumatic Stress Disorder After Trauma: Current Evidence and Future Directions

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie